{"id":"cc-97540","safety":{"commonSideEffects":[{"rate":"null","effect":"Fatigue"},{"rate":"null","effect":"Nausea"},{"rate":"null","effect":"Diarrhea"}]},"_chembl":{"chemblId":"CHEMBL3916385","moleculeType":"Small molecule","molecularWeight":"502.67"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"CD47 is a protein that inhibits phagocytosis, and by targeting it, CC-97540 aims to enhance the immune system's ability to recognize and eliminate cancer cells.","oneSentence":"CC-97540 is a monoclonal antibody targeting CD47.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:49:54.904Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Relapsed or refractory multiple myeloma"}]},"trialDetails":[{"nctId":"NCT07015983","phase":"PHASE2","title":"A Study of CC-97540 (BMS-986353 or Zola-cel), CD19-Targeted NEX-T CAR T Cells, in Participants With Active SLE Despite Immunosuppressants (Breakfree-SLE)","status":"RECRUITING","sponsor":"Juno Therapeutics, Inc., a Bristol-Myers Squibb Company","startDate":"2025-07-14","conditions":"Lupus Erythematosus, Systemic, Lupus Nephritis","enrollment":89},{"nctId":"NCT07335562","phase":"PHASE3","title":"A Study to Compare the Efficacy and Safety of BMS-986353 (Zolacaptagene- Autoleucel / Zola-cel), CD19-CAR T Cells, Versus Standard of Care in Participants With Active Systemic Sclerosis","status":"NOT_YET_RECRUITING","sponsor":"Juno Therapeutics, Inc., a Bristol-Myers Squibb Company","startDate":"2026-04-30","conditions":"Systemic Sclerosis","enrollment":92},{"nctId":"NCT06220201","phase":"PHASE1","title":"A Study to Evaluate the Safety, Tolerability, Efficacy, and Drug Levels of CC-97540 in Participants With Relapsing Forms of Multiple Sclerosis, Progressive Forms of Multiple Sclerosis or Refractory Myasthenia Gravis (MG) (Breakfree-2)","status":"RECRUITING","sponsor":"Juno Therapeutics, Inc., a Bristol-Myers Squibb Company","startDate":"2024-03-28","conditions":"Multiple Sclerosis, Myasthenia Gravis","enrollment":120},{"nctId":"NCT07388277","phase":"PHASE1, PHASE2","title":"CC-97540 in Patients With Antineutrophil Cytoplasmic Antibody-associated Vasculitis","status":"NOT_YET_RECRUITING","sponsor":"Marcela V. Maus, M.D.,Ph.D.","startDate":"2026-07-09","conditions":"Antineutrophil Cytoplasmic Antibody-associated Vasculitis","enrollment":12},{"nctId":"NCT05869955","phase":"PHASE1","title":"A Study of CC-97540, CD-19-Targeted Nex-T CAR T Cells, in Participants With Severe, Refractory Autoimmune Diseases (Breakfree-1)","status":"RECRUITING","sponsor":"Juno Therapeutics, Inc., a Bristol-Myers Squibb Company","startDate":"2023-09-13","conditions":"Systemic Lupus Erythematosus, Idiopathic Inflammatory Myopathy, Systemic Sclerosis","enrollment":270},{"nctId":"NCT04231747","phase":"PHASE1","title":"A Study of CC-97540, CD19-targeted NEX-T Chimeric Antigen Receptor (CAR) T Cells, in Subjects With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma","status":"COMPLETED","sponsor":"Juno Therapeutics, a Subsidiary of Celgene","startDate":"2020-05-21","conditions":"Lymphoma Non-Hodgkin, Agressive Lymphoma, Diffuse-large B-cell Lymphoma (DLBCL)","enrollment":24}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["BMS-986353","Zola-cel","Zolacabtagene autoleucel","CD19-Targeted NEX-T CAR T Cells"],"phase":"phase_2","status":"active","brandName":"CC-97540","genericName":"CC-97540","companyName":"Juno Therapeutics, Inc., a Bristol-Myers Squibb Company","companyId":"juno-therapeutics-inc-a-bristol-myers-squibb-company","modality":"Small molecule","firstApprovalDate":"","aiSummary":"CC-97540 is a monoclonal antibody targeting CD47. Used for Relapsed or refractory multiple myeloma.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}